Warts
Also known as: Verruca, Verruca vulgaris, Verrucous, Verruca plantaris, Plantar
Methodology & AI Transparency ⓘ
Warts Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Warts are growths on your skin caused by an infection with humanpapilloma virus, or HPV .
- 2 Real-world patient consensus: Synonyms for Warts (B07.9): Verruca, Verruca vulgaris, Verrucous (Skin & Dermatology).
- 3 Typical cash cost range: Differential triage of Warts (B07.9) utilizes or targeted biologics [Warts B07.9].
- 4 Top reported side effects / signs: Key Skin & Dermatology biomarkers for Warts (B07.9): Fasting Lipids & in Warts (B07.9: ALT (if systemic) & 25-Hydroxy Vitamin D in Warts (B07.9: & hs-CRP) (25(OH)D 40–65 ng/mL (B07.9)).
Ask our AI Specialists anything about Warts
What Is Warts?
Warts are growths on your skin caused by an infection with humanpapilloma virus, or HPV . Types of warts include : Common warts, which often appear on your fingers Plantar warts, which show up on the soles of your feet Genital warts , which are a sexually transmitted infection (STI) Flat warts, which appear in places you shave frequently In children, warts often go away on their own. In adults, they tend to stay. If they hurt or bother you, or if they multiply, you can remove them. Chemical skin treatments usually work. If not, various freezing, surgical and laser treatments can remove warts.
Pathophysiology, Underlying Causes & Clinical Presentation
Warts (B07.9) alters skin & dermatology homeostasis through or pilosebaceous follicular in Warts (B07.9: hyperkeratinization); Cross-referenced with NIH MeSH (Warts), clinical remission targets 25-Hydroxy Vitamin D in Warts (B07.9: & hs-CRP) within 25(OH)D 40–65 ng/mL (B07.9).
Common Symptoms & Clinical Signs
- • Common warts, which often appear on your fingers
- • Plantar warts, which show up on the soles of your feet
- • Presentation of Warts (B07.9): persistent erythematous plaques, in Warts (B07.9: scaly patches, pruritic)
- • Secondary Warts clinical sign: compromised epidermal barrier in Warts (B07.9: with dryness, fissuring,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Warts Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B07.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Warts (B07.9: ALT (if systemic) | Within baseline reference limits (B07.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Warts (B07.9: & hs-CRP) | 25(OH)D 40–65 ng/mL (B07.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Warts (B07.9: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (B07.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Warts
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Salicylic Acid (Clear Medicated Corn Removers) Salicylic Acid • RxCUI 240559 | Over-the-Counter Clinical Monograph | 74% | $0.0135 | $ 9.47 /mo |
| Mavorixafor Xolremdi • RxCUI 2684026 | CXC Chemokine Receptor 4 Antagonist | 80% | $3.4900 | $ 149.85 /mo |
| Silver Nitrate Applicator Styptstix, Avoca Flexible Caustic Applicator • RxCUI 1536601 | FDA Prescription Therapeutic Agent | 81% | $0.1197 | $ 13.35 /mo |
| H-Warts Formula (Phytolacca Decandra, Thuja Occidentalis) H-Warts Formula • RxCUI RXN-B61077001 | Over-the-Counter Clinical Monograph | 78% | $2.6700 | $ 200.74 /mo |
| Podofilox Condylox • RxCUI 312466 | Decreased Mitosis | 88% | $124.0886 | $ 47.55 /mo |
| Podophyllum Resin Podocon 25 • RxCUI RXN-713352925-1790 | FDA Prescription Therapeutic Agent | 87% | $2.1900 | $ 97.20 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Warts)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Fixed-dose combination Cal/BD foam on the work productivity of patients with Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Journal of the European Academy of Dermatology and Venereology : JEADV • 2022-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35297108 ↗ |
| Can This Approach Help? Inside the Latest Research on Deucravacitinib onset of action and maintenance of response in phase 3 plaque Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis skin flare-ups skin flare-ups. The Journal of dermatological treatment • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38945549 ↗ |
| New Insights on Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin: What a 378-Participant Study Found Of the 357 women (mean [SD] age, 61 [9.9] years) included in the analysis, 182 (51.0%) were treated in the supine position and 175 (49.0%) in prone. JAMA oncology • 2022-07-01 • Phase III Randomized Trial | N = 378 | 87/100 | PMID 35616948 ↗ |
Warts Patient Community & “People Like Me” Threads
Filter Warts community threads and patient logs by age, biological sex, dosage, and treatment duration.